Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113326 | 0.83 | TAAR1 (0.48) | TAAR1GAABACE1GABRA1GABRG2 | |
| SCHEMBL28179325 | 0.83 | TSHR (0.43) | GABRA1GABRG2GABRB3CYP3A4TSHR | |
| SCHEMBL28542074 | 0.83 | TAAR1 (0.42) | TAAR1GAABACE1CYP3A4TSHR | |
| SCHEMBL111658 | 0.79 | TAAR1 (0.47) | TAAR1GAABACE1CYP3A4TSHR | |
| SCHEMBL7997992 | 0.77 | TAAR1 (0.41) | TAAR1GAABACE1CYP3A4TSHR | |
| SCHEMBL8370064 | 0.77 | TAAR1 (0.41) | TAAR1GAABACE1CYP3A4TSHR | |
| Ammonia Solution, Strong SCHEMBL3451387 | 0.76 | TAAR1 (0.39) | TAAR1GAABACE1CYP3A4TSHR | |
| SCHEMBL620083 | 0.74 | TAAR1 (0.42) | TAAR1GAABACE1GABRA1GABRG2 | |
| SCHEMBL2123567 | 0.74 | CYP3A4 (0.42) | GABRA1GABRG2GABRB3CYP3A4TSHR | |
| SCHEMBL3061211 | 0.74 | TAAR1 (0.42) | TAAR1GAAGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4678641-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | CYTOKINETICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| WO-2025111184-A1 | SUBSTITUTED TETRAHYDROQUINOLINE AND TETRAHYDROQUINOXALINE HERBICIDES | FMC CORPORATION (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4545079-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Toray Industries, Inc. (JP) | 2025-04-30 | — | — | EP | disclosed |
| CN-119403554-A | Therapeutic or prophylactic agent for amyotrophic lateral sclerosis | 东丽株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20240368091-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-17 | — | — | US | disclosed |
| US-6815546-B2 | ANTICANCER AGENTS | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-11-09 | — | — | US | disclosed |
| EP-1338599-A1 | Optically pure analogues of Camptothecin | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-08-27 | — | — | EP | disclosed |
| EP-1165565-B1 | OPTICALLY PURE CAMPTOTHECIN ANALOGUES | SOD CONSEILS RECH APPLIC (FR) | 2003-06-04 | — | — | EP | disclosed |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2003-01-02 | — | — | US | disclosed |
| EP-1165565-A1 | OPTICALLY PURE CAMPTOTHECIN ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000050427-A1 | OPTICALLY PURE CAMPTOTHECIN ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-08-31 | — | — | WO | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0773944-A1 | BENZYL-IMIDAZOPYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003403-A1 | BENZYL-IMIDAZOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | TAAR1 2133/4885GAA 2235/4885BACE1 739/4885 |
| US-20240368091-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, MUSK, MYLK | TAAR1 2013/4885GAA 3971/4885BACE1 871/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | TAAR1 983/4885GAA 4217/4885BACE1 1013/4885 |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | TAAR1 468/4885GAA 1312/4885BACE1 4003/4885 |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | MYLK2, MUSK, MYLK | TAAR1 2013/4885GAA 3971/4885BACE1 871/4885 |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP1, TOP2A, TYMP | TAAR1 4717/4885GAA 1683/4885BACE1 3424/4885 |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNT2, RYR1 | TAAR1 2164/4885GAA 4428/4885BACE1 260/4885 |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | MCL1, BRCA1, API5 | TAAR1 2935/4885GAA 3903/4885BACE1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.